RT @drdavidliew: Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on abou
Tweet Content
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3
Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking!
POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
Show on Archive Page
On
Display in Search Results
On
PDQ
Off